Buscador de ensayos clínicos de Fight CRC
NCT ID | Title | Fase | Date Added | Ubicación | Prior IO Allowed | CRC-directed | Status | Drogas | Etiquetas |
---|---|---|---|---|---|---|---|---|---|
NCT ID NCT03668431 |
TitleDabrafenib + Trametinib + PDR001 en cáncer colorrectal | Fase
Fase 2
|
Date Added 2018-09-12 |
Ubicación
Massachusetts, United States
|
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas
Dabrafenib, PDR001, Trametinib, Mekinist, Tafinlar |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03667170 |
TitleKN035 for dMMR/MSI-H Advanced Solid Tumors | Fase
Fase 2
|
Date Added 2018-09-12 |
Ubicación
China
|
Prior IO Allowed No |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas |
Etiquetas
MSI-H/ MMRd
|
NCT ID NCT03658785 |
TitleInmunoterapia para el tratamiento de tumores sólidos avanzados | Fase
Fase 1
|
Date Added 2018-09-05 |
Ubicación
China
|
Prior IO Allowed Sí |
CRC-directed No |
Status
Reclutamiento
|
Drogas
Aldesleukin, Cyclophosphamide, Fludarabine, TIL |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03657641 |
TitleRegorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer | Fase
Fase 1
|
Date Added 2018-09-05 |
Ubicación
California, United States
Florida, United States |
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Activo, no recluta
|
Drogas
Pembrolizumab, Regorafenib, Keytruda, Stivarga |
Etiquetas
MSS/ MMRp
|
NCT ID NCT03650348 |
TitlePRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | Fase
Fase 1
|
Date Added 2018-08-28 |
Ubicación
California, United States
Louisiana, United States New York, United States Ohio, United States Texas, United States |
Prior IO Allowed Sí |
CRC-directed No |
Status
Activo, no recluta
|
Drogas
PRS-343 in Combination with Atezolizumab, Tecentriq |
Etiquetas
MSS/ MMRp
|
NCT ID NCT03638206 |
TitleAutologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | Fase
Fase 1/Fase 2
|
Date Added 2018-08-20 |
Ubicación
China
|
Prior IO Allowed No |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas
CAR-T cell immunotherapy |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03638297 |
TitlePD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer | Fase
Fase 2
|
Date Added 2018-08-20 |
Ubicación
China
|
Prior IO Allowed No |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas
PD-1 antibody + cox inhibitor |
Etiquetas
MSI-H/ MMRd
|
NCT ID NCT03626922 |
TitleStudy of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients | Fase
Fase 1
|
Date Added 2018-08-13 |
Ubicación
Florida, United States
Illinois, United States Michigan, United States Minnesota, United States Pennsylvania, United States |
Prior IO Allowed No |
CRC-directed Sí |
Status
Activo, no recluta
|
Drogas
Dexamethasone, oxaliplatin, Pembrolizumab, Pemetrexed, Alimta, Eloxatin, Keytruda |
Etiquetas
MSS/ MMRp
|
NCT ID NCT03608046 |
TitleAvelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer | Fase
Fase 2
|
Date Added 2018-07-31 |
Ubicación
Bélgica
|
Prior IO Allowed No |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas
Avelumab, Cetuximab Injection, Irinotecan |
Etiquetas
MSS/ MMRp
|
NCT ID NCT03600883 |
TitleA Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) | Fase
Phase 1, Phase 2
|
Date Added 2018-07-26 |
Ubicación
California, United States
Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Indiana, United States Maryland, United States Massachusetts, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Bélgica Brasil Canadá Francia Alemania Greece Hungary Japón Corea, República de Portugal Romania España Suiza |
Prior IO Allowed Sí |
CRC-directed No |
Status
Activo, no recluta
|
Drogas
Anti PD-1/L1, Midazolam, Sotorasib |
Etiquetas
MSS/ MMRp
|